Novartis denies potential split with Sandoz
pharmafile | November 15, 2018 | News story | Business Services, Manufacturing and Production | Business, M&A, MA, Novartis, Sandoz, acquisition, mergers
Swiss newspaper Tages-Anzeiger has reported that Novartis is preparing for a split with long-term partner Sandoz. The two companies merged in 1996.
“Sandoz will be split off, that is the informal information that we have gotten,” a Tages-Anzeiger employee said to Reuters. The Swiss newspaper had previously reported that Novartis CEO Vas Narasimhan had planned to split Sandoz off from the rest of the company.
However Novartis have firmly denied the potential for a split having called the newspaper’s report “speculation”.
“We’re completely committed to the Sandoz business, and we’re looking at transforming it and making it as strong as it can be in the global generics business,” Novartis spokesman Sreejit Mohan said to Reuters.
Mohan added that retaining Sandoz was “the fundamental focus right now.” He continued in noting that: “That’s essentially been the message that we’ve been delivering, so I have no idea how that led to saying ‘split off.”
Louis Goss
Related Content
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
Vertex to acquire Alpine Immune Sciences for $4.9bn
Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive …
Johnson & Johnson to acquire Shockwave Medical
Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a …